RxDoctor Payments Data

Ronald Hopping

Corneal and Contact Management · Houston, TXNPI 1649324542

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (48.9%), consulting fees and entertainment — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Sight Sciences, Inc. at 37.4% of the total. Reporting peaked in 2019 at $1,135 and has fallen 88.4% since, to $132 in 2025.

$2,307in general payments, 2019–2025

Across 40 payments — averaging $57.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$863
  • Optos, Inc.$572
  • Alcon$192
  • Bausch & Lomb Americas Inc.$161
  • ABB Con-cise Optical Group LLC$95
  • AbbVie$83
  • plus $342 from 8 others

What the payments were for

  • Consulting fees$70030%
  • Food & beverage$1,12849%
  • Entertainment$47821%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,307 in reported general payments places this provider in the 65th percentile of 103 corneal and contact management providers in Texas.

See all corneal and contact management providers in Texas

Medicare billing

Part B allowed, 2024
$51,780
Medicare patients
222
Services billed
578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine14$22,156
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat18$569
Latanoprost43$502
Ofloxacin16$164
ErythromycinErythromycin Base15$155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$83$22,15614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 103 corneal and contact management providers in Texas.

Other corneal and contact management in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →